Medidata Platform Enhances Clinical Trial Efficiency for Bristol Myers Squibb –

What You Ought to Know:

– Medidata, a Dassault Systèmes model and a frontrunner in medical trial options for the life sciences business, has introduced an prolonged and expanded partnership with Bristol Myers Squibb (BMS).

–  This collaboration goals to reinforce medical analysis processes, enhance affected person outcomes, and foster developments in customized healthcare. 

Medidata and Bristol Myers Squibb Strengthen Partnership to Advance Medical Analysis and Personalised Healthcare 

As a part of the settlement, Bristol Myers Squibb will proceed using the Medidata Platform whereas exploring further capabilities inside Medidata’s suite of merchandise. These embody: 

– AI and superior analytics to derive deeper insights from medical trial information. 

– Progressive information administration options to streamline trial operations. 

– The Medidata Medical Information Studio, a newly launched device designed to handle, monitor, and analyze medical trials successfully. 

This strategic partnership extension will allow Bristol Myers Squibb to strengthen engagement with trial websites and sufferers, optimize processes, and speed up the supply of life-changing therapies to these in want. By leveraging cutting-edge expertise, each organizations goal to set new benchmarks in medical analysis and customized remedy growth.